Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia

Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia

(2015) M. Dennis et al.   BLOOD

Iron(iii)-binding of the anticancer agents doxorubicin and vosaroxin

(2015) Katja Dralle Mjos et al.   DALTON TRANSACTIONS

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

(2015) Farhad Ravandi et al.   LANCET ONCOLOGY

Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks

(2015)   Oncotarget

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia

(2014) Robert K. Stuart et al.   BRITISH JOURNAL OF HAEMATOLOGY

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia

(2014) J. E. Lancet et al.   HAEMATOLOGICA

Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation

(2014) Yoshihiko Ichikawa et al.   JOURNAL OF CLINICAL INVESTIGATION

Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues

(2013) Krupa J. Patel et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Doxorubicin-Induced Cardiotoxicity: From Bioenergetic Failure and Cell Death to Cardiomyopathy

(2013) Filipa S. Carvalho et al.   MEDICINAL RESEARCH REVIEWS

Metal Complexes of Quinolone Antibiotics and Their Applications: An Update

(2013) Valentina Uivarosi   MOLECULES

Drugging Topoisomerases: Lessons and Challenges

(2012) Yves Pommier   ACS Chemical Biology

Piperonal ciprofloxacin hydrazone induces growth arrest and apoptosis of human hepatocarcinoma SMMC-7721 cells

(2012) Zhen-yu Shi et al.   ACTA PHARMACOLOGICA SINICA

DNA cleavage and opening reactions of human topoisomerase II  are regulated via Mg2+-mediated dynamic bending of gate-DNA

(2012) S. Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia

(2011) J E Lancet et al.   LEUKEMIA

Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo

(2010) Caroline D. Scatena et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs

(2010) Yves Pommier et al.   CHEMISTRY & BIOLOGY

Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules

(2010) R. H. Advani et al.   CLINICAL CANCER RESEARCH

The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine

(2010) E. J. Walsby et al.   HAEMATOLOGICA

Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance

(2010) Alexandre Wohlkonig et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Voreloxin Is an Anticancer Quinolone Derivative that Intercalates DNA and Poisons Topoisomerase II

(2010) Rachael E. Hawtin et al.   PLoS One

Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models

(2008) Ute Hoch et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Metabolism of (+)-1,4-Dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic Acid (Voreloxin; Formerly SNS-595), a Novel Replication-Dependent DNA-Damaging Agent

(2008) M. J. Evanchik et al.   DRUG METABOLISM AND DISPOSITION

DNA repair in response to anthracycline–DNA adducts: A role for both homologous recombination and nucleotide excision repair

(2007) Damian M.S. Spencer et al.   MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS